No Correlation of Intensity of Phlebotomy Regimen With Risk of Thrombosis in Polycythemia Vera: Evidence From ECLAP and CYTO-PV Clinical Trials
The conclusions obtained from this meta-analysis indicate that the frequency of phlebotomies in patients with polycythemia vera receiving hydroxyurea does not represent a risk factor for future thrombosis in patients with polycythemia vera and does not support the need to shift from hydroxyurea plus therapeutic phlebotomy to second-line agents, and indirectly reinforce that a low HCT is the key variable to reduce the thrombotic risk in PV patients.
Haematologica
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology